Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response correctly captures key FDA label elements for complex sleep behaviors, including the contraindication, warning/precaution content, and patient counseling/discontinuation instructions, with no contradictions to the supplied labeling excerpts.
Category Scores
Accurate Statements
Complex sleep behaviors (e.g., sleep-walking, sleep-driving, other activities while not fully awake) may occur following the first or any subsequent use.
Supported by Label 5.1 (Complex Sleep Behaviors may occur following first or any subsequent use).
Patients can be seriously injured or injure others; injuries may result in a fatal outcome.
Supported by Label 5.1 (serious injury/injury to others; fatal outcome possible).
Other complex sleep behaviors (preparing and eating food, making phone calls, or having sex) have been reported.
Supported by Label 5.1 (examples listed).
Patients usually do not remember these events.
Supported by Label 5.1 (events usually not remembered).
Complex sleep behaviors may occur with Zolpidem Tartrate Tablets alone at recommended doses, with or without concomitant alcohol or other CNS depressants.
Supported by Label 5.1 (may occur alone and/or with alcohol/CNS depressants).
Discontinue Zolpidem Tartrate Tablets immediately if a patient experiences a complex sleep behavior.
Supported by Label 5.1 (discontinue immediately) and reflected in counseling/contraindication references.
Contraindication: patients who have experienced complex sleep behaviors after taking Zolpidem Tartrate Tablets.
Supported by Label 4 (contraindicated in patients who experienced complex sleep behaviors after taking Zolpidem Tartrate Tablets).
Patient counseling includes instructing patients/families that complex sleep behaviors may occur and that serious injuries and death have occurred during episodes.
Supported by Label 17 (includes risk of serious injury and death).
Patients should be told to discontinue Zolpidem Tartrate Tablets and notify their healthcare provider immediately if they develop these symptoms.
Supported by Label 17 (discontinue and notify immediately).
Unsupported Statements
The response implies the instruction 'discontinue immediately' is tied specifically to a boxed warning via 'see Boxed Warning, Warnings and Precautions (5.1)'
The supplied excerpts do not confirm the presence of a boxed warning; it states patient counseling references 'see Boxed Warning' but the model response does not provide a label excerpt showing a boxed warning for this topic. This is not a substantive contradiction to the factual safety content, but the boxed-warning framing is not fully verifiable from the provided text.
Contradictions
Low
AI Statement
Zolpidem is generic for Ambien.
Label Reference
No such statement is supported or contradicted in the provided FDA label excerpts for complex sleep behaviors/contraindications.
Important Omissions
No omissions identified relative to the specific claim category evaluated (complex sleep behaviors).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
All core warning/precaution and contraindication elements related to complex sleep behaviors are accurately represented; no unsafe instructions are added. Minor verification uncertainty exists only around boxed-warning framing not evidenced in the provided excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Boxed-warning framing is not fully supported by the provided excerpts, though the substantive discontinuation guidance and warning content are consistent with the label text shown.
Suggested Improvement
Avoid asserting or relying on boxed-warning status; reference the supplied sections (4 and 5.1 and 17) directly without implying boxed-warning verification beyond the provided text.